A Randomized, Double-blind, Multicentre, Event-driven, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Symptomatic Chinese Adults With Asthma (BAIYUN)
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- AstraZeneca
- 入组人数
- 1,000
- 试验地点
- 102
- 主要终点
- Time to first severe asthma exacerbation
研究概览
简要总结
An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.
详细描述
This is a randomized, double-blind, multicenter, event-driven, parallel group, Phase III study to assess the efficacy and safety of budesonide and albuterol metered dose inhaler (MDI) versus albuterol sulfate (AS) MDI in symptomatic Chinese adults with asthma. Both treatments will be administered as needed in response to asthma symptoms or prior to exercise. Approximately 1000 participants who meet the eligibility criteria will be randomized.
The study will consist of 3 periods:
- Screening period: 14 to 28 days
- Treatment period: minimum of 24 weeks and maximum of 52 weeks
- Safety follow-up period: occur 2 weeks (± 4 days) after Visit 8, EOS or PDV, whichever occurs first
1000 participants who meet the eligibility criteria will be randomly assigned in a 1:1 ratio to receive one of the following 2 treatments to be used as reliever therapy on top of usual maintenance treatment:
- BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 µg) as needed
- AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) as needed
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented physician-diagnosed asthma for at least 12 months prior to Visit 1
- •Receiving 1 of the scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1
- •Pre-bronchodilator FEV1 of ≥ 40% to < 90% predicted normal value for adults.
- •Documented reversibility to albuterol
- •A documented history of at least one severe asthma exacerbation within 12 months before Visit 1
- •ACQ-7 score ≥ 1.5 assessed at Visit 1
- •ACQ-5 score ≥ 1.5 assessed at Visit 2
- •Receiving inhaled SABA as needed prior to Visit 1 for at least 3 months
- •Use of Sponsor-provided salbutamol sulfate inhalation aerosol as needed medication due to asthma symptoms on at least 3 days during the last week of the run-in period before Visit 2
- •Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited
- •Able to perform acceptable and reproducible PEF measurements as assessed by the investigator
- •BMI < 40 kg/m2
- •Negative pregnancy test (urine at Visit 1) for female participants of childbearing potential
- •Women of childbearing potential must agree to prevent pregnancy
- •Compliance: must be willing to remain at the study site as required per protocol and complete all visit assessments
排除标准
- •Chronic obstructive pulmonary disease or other significant lung disease
- •Oral/SCS use (any dose) within 6 weeks before Visit 1
- •Chronic use of OCS ≥ 3 weeks use in 3 months prior to Visit 1
- •Having received any marketed or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication
- •Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months before Visit 1
- •Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within last 5 years of Visit 1
- •Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks of Visit 1
- •Upper respiratory infection involving antibiotic treatment not resolved within 7 days before Visit 1
- •Clinically significant laboratory abnormalities
- •Historical or current evidence of a clinically significant disease
- •Cancer not in complete remission for at least 5 years before Visit 1
- •History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity
- •Have a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients
- •Inability to abstain from protocol-defined prohibited medications during the study
- •Having received a live attenuated vaccination within 7 days of Visit 1
- •Currently pregnant or breastfeeding
- •Participants who experience > 1 asthma exacerbation during the screening period
研究组 & 干预措施
BDA MDI
BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg)
干预措施: Budesonide/Albuterol metered dose inhaler, MDI (Combination Product)
AS MDI
AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg)
干预措施: Albuterol sulfate metered dose inhaler, MDI (Combination Product)
结局指标
主要结局
Time to first severe asthma exacerbation
时间窗: 24 to 52 weeks
The efficacy of BDA MDI administered as needed compared with AS MDI on severe asthma exacerbation risk over the 24 to 52 week treatment period.
次要结局
- Severe asthma exacerbation rate (annualized)(24 to 52 weeks)
- Total SCS exposure over the treatment period(24 to 52 weeks)
- ACQ-5 responder (≥ 0.5 decrease)(Week 24)
- AQLQ+12 responder (≥ 0.5 increase)(Week 24)